Abstracts tagged "Midkine"

Abstract Number: 1460 • 2014 ACR/ARHP Annual Meeting
Midkine, a Growth Factor, May Play a Pathophysiological Role in Patients with Rheumatoid Arthritis
Emiko Shindo, Tomoko Hasunuma, Shotaro Masuoka, Mai Kawazoe, Hiroshi Sato, Natsuki Fujio, Kotaro Shikano, Makoto Kaburaki, Sei Muraoka, Nahoko Tanaka, Kaichi Kaneko, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Midkine (MK) is known as a heparin-binding growth factor. Recent studies revealed that MK has various functions such as cell proliferation, differentiation, and apoptosis…
Abstract Number: 2643 • 2013 ACR/ARHP Annual Meeting
Midkine Is a Novel Prognostic Factor In Patients With Vasculitis Syndrome
Yoshie Kusunoki¹, Yutaka Okano¹, Natsuko Kusunoki², Natsuki Fujio², Mai Kawazoe², Emiko Shindo², Kotaro Shikano², Makoto Kaburaki², Sei Muraoka², Kanako Kitahara², Kaichi Kaneko², Nahoko Tanaka², Tatsuhiro Yamamoto², Kenji Takagi², Tomoko Hasunuma², Hirahito Endo² and Shinichi Kawai², ¹Center for Arthritis and Rheumatic Diseases, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Midkine (MK) is a heparin-binding growth factor, promotes growth, survival, and migration of various cells. Recently several reports show that MK may also play…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].